Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1567623 | 0.91 | MTNR1A (0.54) | CYP19A1TBXAS1SIGMAR1IDO1 | |
| SCHEMBL80413 | 0.89 | SIGMAR1 (0.56) | CYP19A1TBXAS1SIGMAR1 | |
| SCHEMBL31522110 | 0.87 | CYP19A1 (0.49) | CYP19A1TBXAS1SIGMAR1IDO1 | |
| SCHEMBL1125535 | 0.87 | CYP19A1 (0.49) | CYP19A1TBXAS1SIGMAR1IDO1 | |
| SCHEMBL18440732 | 0.85 | CYP19A1 (0.55) | CYP19A1TBXAS1SIGMAR1IDO1 | |
| SCHEMBL6077542 | 0.84 | CYP19A1 (0.54) | CYP19A1TBXAS1SIGMAR1IDO1 | |
| SCHEMBL10551218 | 0.84 | CYP19A1 (0.54) | CYP19A1TBXAS1SIGMAR1IDO1 | |
| SCHEMBL5541899 | 0.84 | CYP19A1 (0.54) | CYP19A1TBXAS1SIGMAR1 | |
| SCHEMBL1567240 | 0.84 | CYP19A1 (0.54) | CYP19A1TBXAS1SIGMAR1 | |
| SCHEMBL7898127 | 0.82 | IDO1 (0.52) | CYP19A1TBXAS1SIGMAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
| US-6133446-A | Heterocyclic compounds for the treatment of CNS and cardiovascular disorders | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| US-5877317-A | Heterocyclic compounds for the treatment of CNS and cardiovascular disorders | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0737189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018118-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
| EP-0135177-B1 | BENZOCYCLOALKANE DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1989-12-06 | — | — | EP | disclosed |
| EP-0105735-A2 | Herbicidal ureas and process for preparation | UNION CARBIDE CORPORATION (US) | 1984-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | TNF, CXCL8, MPO | CYP19A1 707/4885TBXAS1 15/4885SIGMAR1 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.